BIOVENTUS INC. (BVS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-27..
Quick ratio
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 152.45M USD | Liabilities, Current |
| Cash and equivalents | 29.46M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 138.41M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 79.81M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-27 | (m) | $152.45M | $29.46M | (m) | $138.41M | $79.81M | (m) |
| 2026-03-28 | (m) | $148.09M | $35.85M | (m) | $120.53M | $83.19M | (m) |
| 2025-12-31 | (m) | $160.38M | $51.24M | (m) | $128.30M | $82.24M | (m) |
| 2025-09-27 | (m) | $161.75M | $42.16M | (m) | $130.40M | $96.27M | (m) |
| 2025-06-28 | (m) | $185.68M | $32.91M | (m) | $132.37M | $96.47M | (m) |
| 2025-03-29 | (m) | $174.75M | $22.80M | (m) | $118.08M | $94.05M | (m) |
| 2024-12-31 | (m) | $210.40M | $41.58M | (m) | $127.39M | $92.47M | (m) |
| 2024-09-28 | (m) | $211.49M | $43.07M | (m) | $121.92M | $90.03M | (m) |
| 2024-06-29 | (m) | $231.46M | $31.99M | (m) | $137.31M | $87.61M | (m) |
| 2024-03-30 | (m) | $173.32M | $25.17M | (m) | $125.54M | $97.00M | (m) |
| 2023-12-31 | (m) | $175.50M | $36.96M | (m) | $122.79M | $91.33M | (m) |
| 2023-09-30 | (m) | $160.84M | $26.83M | (m) | $112.90M | $97.56M | (m) |
| 2023-07-01 | (m) | $179.10M | $29.39M | (m) | $119.64M | $96.28M | (m) |
| 2023-04-01 | (m) | $196.06M | $47.10M | (m) | $118.54M | $87.95M | (m) |
| 2022-12-31 | (m) | $304.02M | $31.81M | (m) | $136.65M | $85.41M | (m) |
| 2022-10-01 | (m) | $288.37M | $34.36M | (m) | $132.19M | $76.95M | (m) |
| 2022-07-02 | (m) | $198.87M | $41.00M | (m) | $143.02M | $69.08M | (m) |
| 2022-04-02 | (m) | $171.52M | $27.37M | (m) | $119.29M | $64.69M | (m) |
| 2021-12-31 | (m) | $180.86M | $43.93M | (m) | $124.96M | $61.69M | (m) |
| 2021-10-02 | (m) | $160.71M | $80.92M | (m) | $105.44M | $36.56M | (m) |
| 2021-07-03 | (m) | $158.19M | $136.06M | (m) | $102.03M | $34.02M | (m) |
| 2021-04-03 | (m) | $149.03M | $124.25M | (m) | $89.47M | $39.81M | (m) |
| 2020-12-31 | (m) | $122.59M | $86.84M | (m) | $88.28M | $29.12M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.